Panel Discussion: The Ethics and Impact of Gene Editing
Moderator: Good evening, everyone. Today’s discussion will be about gene editing, a topic that has been making headlines recently due to its potential impact on healthcare and society as a whole. With us today are four experts in the field who will share their insights and opinions on this issue. Let me introduce our panelists.
Firstly, we have Dr. Jane Smith, a geneticist who has been researching gene editing for over 20 years. Next is Dr. Mark Johnson, an ethicist who specializes in the social implications of new technologies like gene editing. Our third panelist is Ms. Sarah Lee, a patient advocate who suffers from Huntington’s disease and believes that gene editing could offer hope to many patients with genetic disorders like hers. Finally, we have Mr. John Miller, a journalist who has covered science and technology for several major publications.
Let me start by asking Dr. Smith about the technical aspects of gene editing – how does it work?
Dr Smith: Thank you for having me here today. Gene editing refers to the process of altering DNA sequences within cells using targeted molecular tools such as CRISPR-Cas9 or TALEN systems.
Moderator: And what are some applications of this technology that you find particularly exciting?
Dr Smith: One application is in correcting genetic mutations that cause diseases such as cystic fibrosis or sickle cell anemia by repairing them at the molecular level before they can manifest into symptoms or complications later in life.
Another use case would be enhancing crops with beneficial traits such as drought resistance, improved yield or increased nutritional content through modifying their genes.
Panelist Johnson let me ask you next regarding ethical concerns surrounding gene-editing being used on humans? What do you think about it?
Dr Johnson: Yes thank you very much for having me here today too! There are certainly many ethical considerations when it comes to using gene editing on humans. While the technology has the potential to eliminate genetic diseases, it also raises questions about what constitutes a ‘normal’ or ‘desirable’ trait.
There are concerns around eugenics as well if we start selecting for certain traits in our offspring such as intelligence or physical appearance, and how that could lead to social inequality and discrimination.
Ms Lee, I understand you have personal experience with Huntington’s disease. Can you share your thoughts on gene editing?
Ms Lee: Yes, thank you for having me here today too! As someone who suffers from a debilitating genetic disorder myself, I can definitely see why gene editing offers hope for many patients like me. It could potentially cure genetic diseases and save countless lives.
However, there is also concern among the patient community about access to this technology – who will be able to afford it? Will insurance companies cover the costs? Will there be any regulations around its use?
Mr Miller, let me ask you next regarding media coverage of gene editing – do you think journalists should focus more on scientific advancements or ethical debates when covering this topic?
Mr Miller: Thank you for having me here today! I believe both aspects are important and deserve equal attention in media coverage of gene editing. Journalists need to explain the science behind these technologies so readers can understand how they work and their implications.
However, it’s equally important to delve into ethical issues surrounding gene editing such as privacy concerns surrounding collection of DNA data by companies offering testing services or regulation around its use in clinical settings.
Moderator: Thank you all for your insights! We have time for one last question – where do you see this field progressing in the next ten years?
Dr Smith: There’s no doubt that new applications of CRISPR-Cas9 system will continue being discovered across different fields including agriculture biotechnology research and human health interventions.
Dr Johnson: Regulation will become very crucial especially when it comes down to defining the boundaries of what’s acceptable in terms of gene editing to ensure that there are no negative consequences.
Ms Lee: I have high hopes for gene editing becoming more widely available and affordable for patients who need it most!
Mr Miller: I think we’ll see increasing media coverage around biotech companies and startups developing new applications of this technology, as well as regulatory debates surrounding its use.
Moderator: Thank you again for joining us today! This has been an enlightening conversation about gene editing and its impact on healthcare and society.